S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

$92.25
-0.72 (-0.77%)
(As of 03/28/2024 ET)
Today's Range
$92.20
$93.84
50-Day Range
$88.96
$100.29
52-Week Range
$85.21
$131.52
Volume
433,076 shs
Average Volume
728,796 shs
Market Capitalization
$21.93 billion
P/E Ratio
22.39
Dividend Yield
N/A
Price Target
$120.40

BioNTech MarketRank™ Stock Analysis

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
30.5% Upside
$120.40 Price Target
Short Interest
Bearish
1.30% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.08mentions of BioNTech in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.10) to ($1.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

517th out of 939 stocks

Biological Products, Except Diagnostic Industry

89th out of 158 stocks

BNTX stock logo

About BioNTech Stock (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Stock Price History

BNTX Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
BioNTech Full Year 2023 Earnings: Misses Expectations
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
BioNTech Q4 Net Profit Plummets
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
3/29/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BNTX
Employees
6,133
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$120.40
High Stock Price Target
$171.00
Low Stock Price Target
$90.00
Potential Upside/Downside
+30.5%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$1.01 billion
Pretax Margin
31.06%

Debt

Sales & Book Value

Annual Sales
$4.13 billion
Cash Flow
$5.10 per share
Book Value
$92.17 per share

Miscellaneous

Free Float
192,083,000
Market Cap
$21.93 billion
Optionable
Optionable
Beta
0.23

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Ugur Sahin M.D. (Age 59)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $1.25M
  • Dr. Ozlem Tureci M.D. (Age 57)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $822.13k
  • Mr. Jens H. Holstein (Age 61)
    CFO & Member of Management Board
    Comp: $1.44M
  • Dr. Sierk Poetting Ph.D. (Age 51)
    MD, COO & Member of Management Board
    Comp: $844.88k
  • Mr. Ryan Richardson (Age 45)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $1.04M
  • Mr. Sean Marett (Age 59)
    Chief Business Officer, Chief Commercial Officer & Member of Management Board
    Comp: $815.63k
  • Dr. James Timothy Patrick Ryan Ph.D. (Age 49)
    Chief Legal Officer & Member of the Management Board
    Comp: $610.91k
  • Mr. Zach Taylor
    Senior Vice President of Corporate Development & Strategy
  • Dr. Katalin Kariko Ph.D.
    Senior VP & External Consultant for RNA Protein Replacement Therapies
  • Dr. Oliver Henning Ph.D.
    Senior Vice President of Operations

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in BioNTech SE:

  • BioNTech SE is actively developing a range of immunotherapies for cancer and infectious diseases, showing a commitment to addressing critical medical needs.
  • The company has a diverse pipeline of product candidates, including BNT122 in Phase II clinical trial for first-line melanoma and BNT311 in Phase II clinical trial for metastatic non-small cell lung cancer, indicating potential for future revenue growth.
  • Collaborations with established pharmaceutical companies like Genentech, Pfizer, and Sanofi provide BioNTech SE with resources, expertise, and potential market access, enhancing its competitive position.
  • The company's focus on developing prophylactic vaccines for various infectious diseases demonstrates a proactive approach to public health challenges, potentially leading to increased demand and revenue diversification.
  • Recent positive developments and advancements in the company's clinical trials may indicate strong potential for future success, influencing investor confidence and stock price performance.

Cons

Investors should be bearish about investing in BioNTech SE for these reasons:

  • Biotechnology investments can be high-risk due to the uncertainty of clinical trial outcomes, regulatory approvals, and market acceptance, which may lead to significant financial losses.
  • The competitive landscape in the biotechnology industry is intense, with other companies also developing innovative therapies, posing challenges to BioNTech SE's market share and profitability.
  • Market volatility and macroeconomic factors can impact biotech stocks, including BioNTech SE, leading to fluctuations in stock price and potential investor anxiety.
  • Dependency on successful clinical trial results for product candidates like BNT122 and BNT311 may introduce delays, setbacks, or failures, affecting the company's revenue projections and investor confidence.
  • Investors should carefully consider the current stock price of BioNTech SE in relation to its financial performance, market position, and growth prospects to make informed investment decisions.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, March 27, 2024. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings
or view top-rated stocks.

What is BioNTech's stock price target for 2024?

10 Wall Street analysts have issued 12-month price targets for BioNTech's shares. Their BNTX share price targets range from $90.00 to $171.00. On average, they predict the company's stock price to reach $120.40 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts price targets for BNTX
or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2024?

BioNTech's stock was trading at $105.54 at the beginning of 2024. Since then, BNTX stock has decreased by 12.6% and is now trading at $92.25.
View the best growth stocks for 2024 here
.

Are investors shorting BioNTech?

BioNTech saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,080,000 shares, an increase of 5.5% from the February 29th total of 2,920,000 shares. Based on an average daily volume of 689,800 shares, the days-to-cover ratio is currently 4.5 days. Approximately 1.3% of the company's shares are sold short.
View BioNTech's Short Interest
.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our BNTX earnings forecast
.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) announced its quarterly earnings results on Monday, November, 6th. The company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $1.26. The firm earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million. BioNTech had a net margin of 24.26% and a trailing twelve-month return on equity of 4.60%. The business's quarterly revenue was down 74.1% on a year-over-year basis. During the same quarter last year, the firm earned $7.04 earnings per share.

What guidance has BioNTech issued on next quarter's earnings?

BioNTech issued an update on its FY 2024 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $4.2 billion.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

BioNTech (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.66%), Primecap Management Co. CA (2.00%), Harding Loevner LP (1.66%), Flossbach Von Storch AG (1.49%), Capital World Investors (0.39%) and Voloridge Investment Management LLC (0.25%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
This page (NASDAQ:BNTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners